πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 89 of 173

  1. US 9326995

    Oxides for wound healing and body repair

    Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9327023

    HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells

    Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9328140

    Modified mini-hepcidin peptides and methods of using thereof

    Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9328129

    Peptidomimetic inhibitors of PSMA

    Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9320814

    Polyplexes of hydrophobically-modified siRNA for delivery of siRNA

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9320734

    Small molecule inhibitors of the pleckstrin homology domain and methods for using same

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9321743

    Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9321820

    Compositions and methods for treating bladder cancer

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9322010

    Fusion molecule based on novel TAA variant

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9321813

    Methods and compositions for cytomegalovirus IL-10 protein

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9321772

    Substituted pyrazolo[3,4-D]pyrimidines and uses thereof

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9321811

    Further novel anti-parasitic compounds

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9320827

    Dendritic macroporous hydrogels prepared by crystal templating

    Expires Mon Apr 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9314488

    Cellular extracts

    Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9314567

    Electro-osmotic pumps, systems, methods, and compositions

    Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9315534

    Radiologic agents for monitoring alzheimer's disease progression and Evaluating a Response to Therapy and processes for the preparation of such agents

    Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9314517

    Parasite vaccine

    Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9309325

    Antibodies and methods of use thereof

    Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9309553

    Lysosomal phospholipase A2 (LPLA2) activity as a therapeutic target for treating systemic lupus erythematosus

    Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9309298

    Anti-bacterial polypeptides and pathogen specific synthetic antibodies

    Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9308206

    Compositions and methods for treating colon cancer

    Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9310365

    Method of diagnosing and treating melioidosis

    Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9309535

    Combination anti-HIV vectors, targeting vectors, and methods of use

    Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9301976

    Compositions comprising perivascular stem cells and nell-1 protein

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9301960

    Methods for inhibiting redox-sensitive GTPases

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9301947

    Ryanodine receptor inhibitors for treatment of T-cell mediated disorders

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9303258

    Method and compositions comprising small RNA agonist and antagonists to modulate inflammation

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9303087

    Monoclonal antibodies that inhibit the Wnt signaling pathway and methods of production and use thereof

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9303064

    Peptide inhibiting matrix metalloproteanases activity and use thereof

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9303042

    Triazolothienopyrimidine compound inhibitors of urea transporters and methods of using inhibitors

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9302120

    Spiro-oxindole MDM2 antagonists

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9302085

    Methods and compositions for facilitating arterial access

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9303068

    D-amino acid derivative-modified peptidoglycan and methods of use thereof

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9297008

    Small activating RNA molecules and methods of use

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9295674

    Metalloporphyrin neurological treatments

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9296693

    Acyl piperidine inhibitors of soluble epoxide hydrolase

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9296798

    Purified linear epitopes from cashew nuts, nucleic acids encoding therefor, and associated methods

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9297015

    Regulated expression of antigen and/or regulated attentuation to enhance vaccine immunogenicity and/or safety

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9296730

    Aurora kinase inhibitors

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9295629

    WNT family-derived peptides and use thereof

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9295715

    Minimizing intestinal dysfunction

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9290474

    Methods for making and using novel semi-synthetic small molecules for the treatment parasitic disease

    Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9290572

    Integrin Ξ±-VΞ²8 neutralizing antibody

    Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9290562

    Transferrin-tumstatin fusion protein and methods for producing and using the same

    Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9289500

    Saccharide-peptide hydrogels

    Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9289131

    Method and apparatus to identify vulnerable plaques with thermal wave imaging of heated nanoparticles

    Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9289408

    High concentration baclofen preparations

    Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9290541

    TCL1 peptides for immunotherapy

    Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.